Biogen Idec profit rises as new multiple sclerosis drug shines
Jan 29 (Reuters) - Biogen Idec Inc on Wednesday said fourth-quarter profit soared 57 percent, helped by strong sales of its new multiple sclerosis drug, Tecfidera.
The U.S. biotechnology company's net profit rose to $457.3 million, or $1.92 per share, in the quarter ended Dec. 31, from $292.1 million, or $1.23 per share, a year earlier.
Excluding special items, Biogen earned $2.34 per share. Analysts on average expected $2.28 per share, according to Thomson Reuters I/B/E/S.
The high-profile multiple sclerosis drug had sales of $398 million for the period. Total sales rose 39 percent to $1.97 billion, beating the analysts' average estimate of $1.93 billion.
- Survivors still alive on South Korean ferry: father |
- Putin risks upstaging talks on defusing Ukraine crisis |
- Ocean floor search for missing Malaysia plane cut short again
- BofA reports first quarterly loss since 2011 on lofty legal bill
- Weak U.S. prices, not inflation, the threat now: Fed's Yellen |